Effect of gonadotrophin-releasing hormone agonist treatment on growth hormone secretion in women with polycystic ovarian syndrome
The suppression of the pituitary-gonadal axis by the administration of gonadotrophin-releasing hormone agonists (GnRH-a) is used occasionally as an adjunct therapy with gonadotrophins for ovulation induction in women with polycystic ovarian syndrome (PCOS), A number of recent clinical studies have suggested that women with polycystic ovaries (PCO) may have disturbances of normal growth hormone (GH) kinetics and alterations in the GH/insulin-like growth factor (IGF)-I system, The purpose of this study was to determine the effect of GnRH-a administration on GH-releasing hormone (GHRH)-stimulated GH release in women with PCOS, Eight women with PCO and six control women were studied before and after 2 months of treatment with the long acting GnRH-a triptoreline (3.75 mg monthly injections), GHRH was given as a single i.v. injection and blood samples for GH measurements were obtained at -15, 0, 30, 60, 90 and 120 min, The GH responses were expressed as the area under the curve (AUC) or the differences from the basal value (Delta(max)). The GH response to GHRH (mean +/- SEM) was lower in women with PCO (AUG 114.9 +/- 43.1 versus 206.2 +/- 28.7 ng/ml/120 min, P < 0.05 and Delta(max) 31.6 +/- 8.2 versus 49.4 +/- 5.8 ng/ml,P < 0.05), After treatment with the GnRH-a, the GH response to GHRH was significantly smaller than before treatment in both groups (PCO AUC 34.6 +/- 9.0 ng/ml/120 min and Delta(max) 12.4 +/- 3.1 ng/ml; controls AUC 148.8 +/- 28.4 ng/ml/120 min and Delta(max) 31.2 +/- 6.1 ng/ml), but the PCO group had a significantly smaller response, These data demonstrate that women with PCO have a reduced GH response to GHRH compared with normal controls and that GnRH-a administration causes a further GH reduction in both groups, Women with PCO have a greater suppression of GH response to GHRH during treatment with GnRH-a, This suggests that a different level of sensitivity in the somatotrophic axis exists in PCOS.
Showing items related by title, author, creator and subject.
Vamvakopoulos, N. C. (1996)Following a brief introduction to the Biology (structure-function) of the steroid hormone receptor superfamily, an updated summary of pathogenic mutations in the steroid, thyroid hormone and vitamin D receptors causing ...
Growth hormone response to submaximal doses of ghrelin remains unchanged during the follicular phase of the cycle Messini, C. I.; Dafopoulos, K.; Malandri, M.; Georgoulias, P.; Anifandis, G.; Messinis, I. E. (2013)Background: Previous data have shown that ghrelin-induced growth hormone (GH) secretion is augmented in women by exogenous but not by endogenous estrogens. The purpose of this study was to examine the response of GH to ...
Pappa, A.; Seferiadis, K.; Fotsis, T.; Shevchenko, A.; Marselos, M.; Tsolas, O.; E.messinis, I. (1999)Gonadotrophin surge attenuating factor (GnSAF) is a new non-steroidal ovarian substance, different from inhibin, which attenuates the pre-ovulatory luteinizing hormone (LH) surge in superovulated women. Human follicular ...